翰森制药(03692)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

03692 翰森制药

已收盘 04-02 16:08:21

39.360

+1.940

+5.18%

最高39.400	最低37.040	成交量2,017万
今开37.880	昨收37.420	日振幅6.31%
总市值2,383亿	流通市值2,383亿	总股本60.55亿
成交额7.81亿	换手率0.33%	流通股本60.55亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"03692","market":"HK","secType":"STK","nameCN":"翰森制药","latestPrice":39.36,"timestamp":1775117301007,"preClose":37.42,"halted":0,"volume":20172507,"delay":0,"changeRate":0.05184393372528054,"floatShares":6055000000,"shares":6055000000,"eps":1.0563692720048279,"marketStatus":"已收盘","change":1.94,"latestTime":"04-02 16:08:21","open":37.88,"high":39.4,"low":37.04,"amount":780824637,"amplitude":0.063068,"askPrice":39.36,"askSize":8000,"bidPrice":39.24,"bidSize":16000,"shortable":3,"etf":0,"ttmEps":1.0563692720048279,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1775611800000},"marketStatusCode":5,"adr":0,"listingDate":1560441600000,"exchange":"SEHK","adjPreClose":37.42,"dividendRate":0.009322,"openAndCloseTimeList":[[1775093400000,1775102400000],[1775106000000,1775116800000]],"volumeRatio":1.407607,"lotSize":2000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/03692","defaultTab":"news","newsList":[{"id":"1145375283","title":"翰森制药3月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1145375283","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145375283?lang=zh_cn&edition=full","pubTime":"2026-04-02 17:02","pubTimestamp":1775120563,"startTime":"0","endTime":"0","summary":"翰森制药集团有限公司于2026年4月2日发布截至2026年3月31日止的股份变动月报表。公告显示，公司于本期未有新增发行、购回或注销股份，已发行股份数量维持6,055,150,070股不变，库藏股数为0股。截至报告期末，公司确认符合香港联交所规定的公众持股量要求。报告期内未有就该可换股债券产生新增发行股份的情况。公告由联席公司秘书钟胜利女士签署。公司表示，将继续严格遵守香港联交所《上市规则》及相关法律法规的要求。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156613610","title":"异动解读 | 业绩超预期且管线催化剂丰富，翰森制药盘中大涨6.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=1156613610","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156613610?lang=zh_cn&edition=full","pubTime":"2026-04-01 16:13","pubTimestamp":1775031196,"startTime":"0","endTime":"0","summary":"翰森制药(03692)今日盘中股价大幅上涨6.09%，表现强劲。消息面上，公司2025年业绩表现超出市场预期，全年收入及净利润同比分别增长23%和27%，达到150.3亿元及55.6亿元人民币。管理层对2026年展望积极，指引产品销售和合作收入将实现双位数增长，并预计研发投入增幅超过30%。此外，公司研发管线在2026年中后期催化剂丰富，多个重点药物（如HS-20093、HS-20089等）将在年内读出关键临床数据并申请上市，今年还将有9款产品启动III期或关键注册临床。这些积极因素共同增强了市场对公司未来增长潜力的信心，推动了股价的上涨。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624932355","title":"交银国际：降翰森制药(03692)目标价至44.5港元 去年业绩超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2624932355","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624932355?lang=zh_cn&edition=full","pubTime":"2026-04-01 15:57","pubTimestamp":1775030223,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，交银国际发布研报称，维持翰森制药“买入”评级，下调目标价至44.5港元。　　翰森制药2025年业绩超预期，2026年创新药销售和BD延续高增长。公司全年收入和净利润同比分别增长23%及27%，各至150.3亿/55.6亿元人民币(下同)，均超该行及市场预期。　　报告指，翰森制药2026年中后期管线全面开花、催化剂丰富。今年还将有9款产品启动III期或关键注册临床。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260401/32118306.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["03692","EWH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623630434","title":"中信里昂：维持翰森制药(03692)“优于大市”评级 目标价下调至40港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2623630434","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623630434?lang=zh_cn&edition=full","pubTime":"2026-03-31 15:50","pubTimestamp":1774943438,"startTime":"0","endTime":"0","summary":"展望未来，预计创新药增长及授权收入将继续成为公司2026年的主要增长动力。","market":"hk","thumbnail":"https://img.zhitongcaijing.com/image/20260331/20260331154244_27710.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260331/20260331154244_27710.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1422889.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["EWH","03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623371898","title":"翰森制药早盘涨超6% 全年纯利55.55亿元同比增长27.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2623371898","media":"新浪港股","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623371898?lang=zh_cn&edition=full","pubTime":"2026-03-31 10:44","pubTimestamp":1774925040,"startTime":"0","endTime":"0","summary":"　　翰森制药盘中涨超7%，截至发稿，股价上涨6.35%，现报35.18港元，成交额2.19亿港元。　　翰森制药日前发布2025年度业绩，该集团取得收入150.28亿元，同比增长22.57%；母公司拥有人应占溢利55.55亿元，同比增长27.07%；拟派发末期股息每股20.00港仙。值得一提的是，截至2025年12月31日止年度，创新药与合作产品销售收入约人民币123.54亿元，占收入比例约82.2%，已成为驱动集团业绩可持续增长的核心动力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-03-31/doc-inhsvwqh2223363.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1583","03692","BK1589","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162487800","title":"异动解读 | 昭衍新药绩后大涨带动板块，翰森制药盘中飙升6.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=1162487800","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162487800?lang=zh_cn&edition=full","pubTime":"2026-03-31 10:00","pubTimestamp":1774922431,"startTime":"0","endTime":"0","summary":"翰森制药今日盘中大幅上涨6.17%，引起了市场的广泛关注。消息面上，港股生物医药股今日全线走高，其中昭衍新药在业绩公布后大涨逾14%，映恩生物-B升逾6%，药明生物、药明康德、泰格医药等亦升逾4%。翰森制药作为生物医药板块的重要成员，在此轮板块普涨行情中同步走强。此次生物医药板块的集体上涨，主要受到昭衍新药亮眼业绩的提振，市场情绪向好，资金流入该板块，从而带动了包括翰森制药在内的多只个股上涨。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"ee4d118e55b1b421073820cd0cff0613","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623625983","title":"315亿现金“弹药”就位，翰森制药能否撬动全球创新药市场？","url":"https://stock-news.laohu8.com/highlight/detail?id=2623625983","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623625983?lang=zh_cn&edition=full","pubTime":"2026-03-30 09:51","pubTimestamp":1774835460,"startTime":"0","endTime":"0","summary":"2026年的春天，对于中国创新药行业而言，是一个检验“成色”的季节。3月29日，翰森制药（03692.HK）发布了2025年全年业绩报告。在医药行业经历资本寒冬洗礼、市场从“炒作估值”转向“验证现金流”的当下，这份财报不仅关乎一家企业，更被视为观察中国创新药头部企业能否穿越周期的窗口。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603303688387014.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603303688387014.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06978","BK1574","BK1161","03692","159992","BK1191","BK1589","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623356664","title":"翰森制药(03692)发布年度业绩 股东应占溢利55.55亿元 同比增长27.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2623356664","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623356664?lang=zh_cn&edition=full","pubTime":"2026-03-29 19:37","pubTimestamp":1774784278,"startTime":"0","endTime":"0","summary":"智通财经APP讯，翰森制药 发布截至2025年12月31日止年度业绩，该集团取得收入150.28亿元，同比增长22.57%;母公司拥有人应占溢利55.55亿元，同比增长27.07%;每股基本盈利0.93元。拟派发末期股息每股20.00港仙。公司在中国产生销售收入的创新药共七款，形成了丰富的产品管线。截至2025年12月31日止年度，创新药与合作产品销售收入约人民币123.54亿元，占收入比例约82.2%，已成为驱动集团业绩可持续增长的核心动力。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1421382.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","03692","BK1583","BK1589"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166728018","title":"翰森制药(03692)将于2026年7月24日派发末期股息每股0.20港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1166728018","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166728018?lang=zh_cn&edition=full","pubTime":"2026-03-29 19:35","pubTimestamp":1774784139,"startTime":"0","endTime":"0","summary":"翰森制药(03692)发布公告，董事会宣派截至2025年12月31日止年度之末期股息每股0.20港元，股东批准日期尚待公布。根据公告，公司股份将于2026年7月3日除净，合资格股东须于2026年7月6日16时30分前办理过户登记。公司将于2026年7月7日至2026年7月9日暂停办理股份过户登记手续，并于2026年7月9日为记录日。预计股息派发日为2026年7月24日。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622282910","title":"翰森制药(03692)：昕越® (伊奈利珠单抗注射液)第三项适应症获国家药监局签发药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2622282910","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622282910?lang=zh_cn&edition=full","pubTime":"2026-03-27 20:22","pubTimestamp":1774614162,"startTime":"0","endTime":"0","summary":"智通财经APP讯，翰森制药(03692)发布公告，于2026年3月25日，创新药昕越® (伊奈利珠单抗注射液)获中国国家药品监督管理局(NMPA)签发的药品注册证书，批准增加适应症：本品与常规治疗药物联合用于治疗抗乙酰胆硷受体(AChR)或抗肌肉特异性酪氨酸激酶(MuSK)抗体阳性的成人全身型重症肌无力(gMG)患者。此为昕越®获批的第三项适应症。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1420787.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"翰森制药(03692)：昕越® (伊奈利珠单抗注射液)第三项适应症获国家药监局签发药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1589","BK1191","03692","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621067887","title":"翰森制药获评MSCI ESG AAA评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2621067887","media":"中国财经报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621067887?lang=zh_cn&edition=full","pubTime":"2026-03-24 19:45","pubTimestamp":1774352700,"startTime":"0","endTime":"0","summary":"3月23日，国际指数公司MSCI公布最新年度环境、社会及管治评级结果，翰森制药ESG评级跃升至全球最高等级“AAA级”。此前，翰森制药已连续三年荣获MSCI ESG评级“AA级”，保持中国制药行业领先地位，稳居全球同行前列。全球制药行业领先在本年度MSCI评级报告中，翰森制药的环境绩效和社会价值贡献进一步获得认可，步入全球ESG领导者行列。MSCI是国际权威的ESG指数及评级机构之一，其评级结果已成为国际资本市场的主流投资参考依据。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-03-24/doc-inhsavws1706814.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["AAA","MSCI","159717","ESG","03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621742600","title":"翰森制药(03692)：HS-10587片获国家药监局签发的药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2621742600","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621742600?lang=zh_cn&edition=full","pubTime":"2026-03-23 07:31","pubTimestamp":1774222293,"startTime":"0","endTime":"0","summary":"智通财经APP讯，翰森制药(03692)发布公告，本集团自主研发的1类新药HS-10587片获中国国家药品监督管理局(NMPA)签发的药物临床试验批准通知书，拟开展用于MTAP缺失的晚期实体瘤的临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417117.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"翰森制药(03692)：HS-10587片获国家药监局签发的药物临床试验批准通知书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK1589","03692","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618513604","title":"每日卖空追踪 | 翰森制药 03月12日卖空量成交65.6万股，卖空比例为9.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618513604","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618513604?lang=zh_cn&edition=full","pubTime":"2026-03-12 16:30","pubTimestamp":1773304236,"startTime":"0","endTime":"0","summary":"翰森制药北京时间03月12日，跌0.36%，卖空量成交65.6万股，较上一交易日减少46.14%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260312163526a6ba5299&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260312163526a6ba5299&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","03692","BK1589","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618902170","title":"世界肾脏日｜警惕“沉默杀手”，药企竞速“护肾”","url":"https://stock-news.laohu8.com/highlight/detail?id=2618902170","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618902170?lang=zh_cn&edition=full","pubTime":"2026-03-12 12:03","pubTimestamp":1773288195,"startTime":"0","endTime":"0","summary":"今年3月12日迎来第21个世界肾脏日，主题为“人人享有肾脏健康：关爱生命，守护地球”，强调个体健康与环境保护的双重关注。更值得警惕的是，CKD起病隐匿，早期常无明显症状，被称为“沉默的杀手”。此外，通过肾脏B超检查，能够观察肾脏形态和结构，排查囊肿、结石等问题。在此背景下，国内外药企加速布局肾病赛道。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260312120402a6b9b780&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260312120402a6b9b780&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01276","LU0359201885.HKD","LU0359202008.SGD","LU0359201612.USD","03692","BK1191","LU2543165471.USD","LU1023057109.AUD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618094075","title":"翰森制药、恒瑞医药等齐发力，国产GLP-1类减重药加速“破圈”","url":"https://stock-news.laohu8.com/highlight/detail?id=2618094075","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618094075?lang=zh_cn&edition=full","pubTime":"2026-03-11 11:32","pubTimestamp":1773199961,"startTime":"0","endTime":"0","summary":"据悉，在减重药物领域，GLP-1类药物成为热门赛道，国内一批药企也积极抢占这一赛道，并逐渐迎来收获。除了翰森制药外，还有一批国产GLP-1类新药正在加速推进临床。值得一提的是，目前已有多个国产GLP-1类新药获批上市。从临床推进到上市落地，国产GLP-1类药物的多点突破，彰显了我国生物医药产业的自主创新实力。未来，随着药企持续加大研发投入，聚焦剂型创新、适应症拓展，国产GLP-1类药物将在全球肥胖防控领域发挥更重要的作用。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031111372197acfd6f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031111372197acfd6f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01276","01801","03692","BK1583","LU0359202008.SGD","LU1023057109.AUD","LU0359201612.USD","BK1589","LU2543165471.USD","LU0359201885.HKD","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618920930","title":"胃肠道安全性表现突出，翰森制药奥莱泊肽破解减肥难题","url":"https://stock-news.laohu8.com/highlight/detail?id=2618920930","media":"动脉新医药","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618920930?lang=zh_cn&edition=full","pubTime":"2026-03-11 08:02","pubTimestamp":1773187336,"startTime":"0","endTime":"0","summary":"奥莱泊肽Ⅲ期数据出炉，翰森制药强势入局减重赛道。由此来看，奥莱泊肽有望跻身全球减重药物“第一梯队”。2025年上半年，翰森制药总收入74.34亿元，其中创新药与合作产品销售收入达61.45亿元，占总收入比例上升至82.7%。翰森制药在这一赛道同样获得了国际巨头认可。同时值得关注的是，依托强大的临床转化能力，翰森制药计划于近期在中国递交奥莱泊肽注射液用于长期体重管理的新药上市申请。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202603110816089547a8ac&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202603110816089547a8ac&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","BK1583","BK1589","03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618940751","title":"减重大战再添中国玩家：翰森奥莱泊肽III期成功，国产GLP-1/GIP双靶点加速入场","url":"https://stock-news.laohu8.com/highlight/detail?id=2618940751","media":"E药经理人","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618940751?lang=zh_cn&edition=full","pubTime":"2026-03-10 21:39","pubTimestamp":1773149950,"startTime":"0","endTime":"0","summary":"中国本土企业在GLP-1双靶点减重药领域正加速追赶全球第一梯队。据悉，奥莱泊肽凭借双靶点协同作用的创新设计，恶心发生率平均不到10%，呕吐发生率平均不到5%。目前，奥莱泊肽计划近期在中国递交新药上市申请，若进展顺利，有望成为中国GLP-1/GIP双靶点前三获批的产品之一。恒瑞医药的HRS9531是GLP-1/GIP双靶点注射剂，减重适应证上市申请已于2025年9月获NMPA受理。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310214535a45ec777&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310214535a45ec777&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0359201612.USD","LU0359202008.SGD","BK1583","03692","LU1023057109.AUD","BK1589","LU2543165471.USD","BK1191","01276","LU0359201885.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618560711","title":"翰森制药盘中异动 急速上涨3.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618560711","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618560711?lang=zh_cn&edition=full","pubTime":"2026-03-10 09:48","pubTimestamp":1773107323,"startTime":"0","endTime":"0","summary":"2026年03月10日早盘09时48分，翰森制药股票出现异动，股价大幅上涨3.02%。截至发稿，该股报34.740港元/股，成交量129.436万股，换手率0.02%，振幅3.32%。翰森制药股票所在的药品行业中，整体涨幅为1.12%。其相关个股中，劲方医药-B、开拓药业-B、英硅智能涨幅较大，振幅较大的相关个股有劲方医药-B、长风药业、君圣泰医药-B，振幅分别为28.10%、12.41%、11.32%。翰森制药公司简介：翰森制药集团有限公司是一家主要从事一系列药品的研发、生产及销售的投资控股公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031009484397ab78d8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031009484397ab78d8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1589","BK1191","03692","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618188607","title":"每日卖空追踪 | 翰森制药 03月09日卖空量成交155.6万股，卖空比例为12.58%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618188607","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618188607?lang=zh_cn&edition=full","pubTime":"2026-03-09 16:30","pubTimestamp":1773045035,"startTime":"0","endTime":"0","summary":"翰森制药北京时间03月09日，涨0.36%，卖空量成交155.6万股，较上一交易日减少32.76%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260309163506a45ae8ed&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260309163506a45ae8ed&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1589","03692","BK1583","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618607912","title":"翰森制药宣布奥莱泊肽减重III期注册研究取得积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2618607912","media":"动脉网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618607912?lang=zh_cn&edition=full","pubTime":"2026-03-09 15:33","pubTimestamp":1773041580,"startTime":"0","endTime":"0","summary":"3月7日，翰森制药宣布其首款减重药奥莱泊肽（HS-20094）Ⅲ期注册研究取得积极结果。该研究在中国33个临床中心开展，604例成年受试者参与，旨在评估奥莱泊肽对比安慰剂治疗48周的疗效与安全性。结果显示，奥莱泊肽组体重降幅显著，最高达19.3%，达成5%体重降幅的受试者比例最高达97.2%，且胃肠道耐受性优异，不良事件发生率及停药率更低。研究主要研究者纪立农教授评价其减重疗效显著，胃肠道耐受性优于同类药物，有助于提升治疗依从性。翰森制药董事会执行董事孙远表示，奥莱泊肽有望成为超重及肥胖人群的优质选择。肥胖是复杂慢性病，奥莱泊肽为每周一次皮下注射用GLP-1/GIP受体双激动剂。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260309154425a45ab182&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260309154425a45ab182&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1589","BK1583","03692","BK1191"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0.1894},{"period":"1month","weight":0.0891},{"period":"3month","weight":0.0371},{"period":"6month","weight":-0.0296},{"period":"1year","weight":0.5476},{"period":"ytd","weight":0.0371}],"compareEarnings":[{"period":"1week","weight":-0.0017},{"period":"1month","weight":-0.0294},{"period":"3month","weight":-0.0131},{"period":"6month","weight":-0.068},{"period":"1year","weight":0.0899},{"period":"ytd","weight":-0.0131}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"翰森制药集团有限公司是一家主要从事一系列药品的研发、生产及销售的投资控股公司。该公司的创新药产品包括阿美乐、豪森昕福、迈灵达、孚来美、恒沐、昕越、圣罗莱等产品。该公司的创新药产品主要应用于抗肿瘤、抗感染、中枢神经系统（CNS）疾病、代谢及其他治疗领域。该公司主要在国内市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.714286,"avgChangeRate":-0.002565},{"month":2,"riseRate":0.428571,"avgChangeRate":-0.01282},{"month":3,"riseRate":0.428571,"avgChangeRate":0.023369},{"month":4,"riseRate":0.571429,"avgChangeRate":0.035248},{"month":5,"riseRate":0.666667,"avgChangeRate":0.019349},{"month":6,"riseRate":0.666667,"avgChangeRate":0.055622},{"month":7,"riseRate":0.571429,"avgChangeRate":-0.000332},{"month":8,"riseRate":0.714286,"avgChangeRate":0.01897},{"month":9,"riseRate":0.571429,"avgChangeRate":-0.033021},{"month":10,"riseRate":0.142857,"avgChangeRate":0.001586},{"month":11,"riseRate":0.714286,"avgChangeRate":0.063467},{"month":12,"riseRate":0.571429,"avgChangeRate":0.016858}],"exchange":"SEHK","name":"翰森制药","nameEN":"HANSOH PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"翰森制药(03692)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供翰森制药(03692)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"翰森制药,03692,翰森制药股票,翰森制药股票老虎,翰森制药股票老虎国际,翰森制药行情,翰森制药股票行情,翰森制药股价,翰森制药股市,翰森制药股票价格,翰森制药股票交易,翰森制药股票购买,翰森制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"翰森制药(03692)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供翰森制药(03692)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}